Observational studyClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Optimizing limited antibody panels for efficient hematological disorders diagnosis by flow cytometry in resource-constrained setting.
Observational study in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Strategies to Overcome Inequities in the Treatment of Patients with Hematologic Malignancies.Current hematologic malignancy reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveFlow cytometry (FC) is an expensive method that is unaffordable for many patients from underprivileged nations. We aimed to reduce the total budget of the test by optimizing a limited antibody panel, guided by morphological assessment. MATERIALS AND
methodsThis retrospective observational study included 395 patients referred for flow cytometry at the Rehman Medical Institute in Peshawar. Bone marrow or peripheral blood samples were immunophenotyped using a limited panel of flow markers after morphological and cytochemical assessments. The samples were stained with fluorochrome-labeled monoclonal antibodies and analyzed using a Cytoflex flow cytometer. Data were analyzed using R and R studio by calculating frequency and percentage for descriptive statistics while results are presented in graphs, tables, and charts.
resultsOut of 395 cases, an acute leukemia panel was requested for 225 (56.9%) cases, a lymphoproliferative panel for 80 (20.3%) cases, an absolute CD4 count for 80 (20.3%) cases, and proximal nocturnal hemoglobinuria (PNH) clone screening for 10 (2.5%) cases. Of the 225 acute leukemia cases, 160 (71.1%) were newly diagnosed and 65 (28.9%) were follow-up cases. In the follow-up cases, 21 (32.3%) were in remission, 13 (19.3%) were not in remission, and 31 (48.4%) were in relapse. 98% of cases of acute leukemia and lymphoproliferative disorders and 100% of cases of PNH and absolute CD4 count were conclusively diagnosed using our limited flow panels. Our panel achieved 74-82% average cost reductions and 61-68% reductions in turnaround time (TAT) compared with established reference laboratories in Pakistan.
conclusionsOptimizing a minimal antibody panel in resource-limited settings enhances flow cytometry-based diagnosis, reduces patient financial burden, enables timely and accurate results, and guides treatment decisions to improve patient outcomes.
Indexed as
Identifiers
41549166What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.